Table 1 Attributes and levels used for the DCE
Attribute | Level used in design | Level used in modelb | ||
|---|---|---|---|---|
Average overall survivala & Remission period | 1 year survival | 3 months remission | 1 | Short |
9 months remission | 1 | Long | ||
3 years survival | 9 months remission | 3 | Short | |
2 years 3 months remission | 3 | Long | ||
5 years survival | 1 year 3 months remission | 5 | Short | |
3 years 9 months remission | 5 | Long | ||
7 years survival | 1 year 9 months remission | 7 | Short | |
5 years 3 months remission | 7 | Long | ||
9 years survival | 2 years 3 months remission | 9 | Short | |
6 years 9 months remission | 9 | Long | ||
Side effects | Mild or moderate | None | 0 | |
20% risk, lasting up to 2 months | 20 | |||
20% risk, lasting longer than 2 months | 20 | |||
40% risk, lasting up to 2 months | 40 | |||
40% risk, lasting longer than 2 months | 40 | |||
60% risk, lasting up to 2 months | 60 | |||
60% risk, lasting longer than 2 months | 60 | |||
Severe | None | None | ||
5% risk, lasting up to 2 months | Some | |||
5% risk, lasting longer than 2 months | Some | |||
10% risk, lasting up to 2 months | Some | |||
10% risk, lasting longer than 2 months | Some | |||
Mode & Frequency of administration | Oral | Daily | Oral | |
Weekly | Oral | |||
Subcutaneous (SC) | 2–3 times per week | SC - high | ||
Weekly | SC - high | |||
Fortnightly | SC - low | |||
Monthly | SC - low | |||
Intravenous (IV) | 2–3 times per week | IV - high | ||
Weekly | IV - high | |||
Fortnightly | IV – low | |||
Monthly | IV - low | |||
Annual out of pocket costsc | $0 | 0 | ||
$500 | 5 | |||
$1500 | 15 | |||
$3000 | 30 | |||
$5000 | 50 | |||